Cargando…

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

BACKGROUND: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women. Understanding dolutegravir exposure in patients with obesity is important for dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mondleki, Enkosi, Banda, Clifford G., Chandiwana, Nomathemba C., Sokhela, Simiso, Wiesner, Lubbe, Venter, Francois, Maartens, Gary, Sinxadi, Phumla Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772744/ https://www.ncbi.nlm.nih.gov/pubmed/36751628 http://dx.doi.org/10.4102/sajhivmed.v23i1.1452

Ejemplares similares

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans
por: Mateza, Somila, et al.
Publicado: (2023)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay
por: Joubert, Andre, et al.
Publicado: (2022)

Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV
por: Banda, Clifford G., et al.
Publicado: (2022)

Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
por: Chandiwana, Nomathemba C., et al.
Publicado: (2021)

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
por: Sinxadi, Phumla Z, et al.
Publicado: (2012)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
por: Johnston, Jenna, et al.
Publicado: (2019)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
por: Griesel, Rulan, et al.
Publicado: (2023)

1498. Geographic differences in weight change on dolutegravir: a prospective cohort study
por: Chen, Geoffrey, et al.
Publicado: (2023)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Objectively measured medication adherence using assays for carvedilol and enalaprilat in patients with heart failure in Mozambique and Nigeria
por: Mwita, Julius Chacha, et al.
Publicado: (2023)

Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection
por: Bekker, Linda-Gail, et al.
Publicado: (2016)

Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV
por: Banda, Clifford G., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study
por: Sinxadi, Phumla Z, et al.
Publicado: (2010)

Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
por: Pepperrell, Toby, et al.
Publicado: (2020)

Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections: Moving towards best practice
por: Peters, Remco P.H., et al.
Publicado: (2022)

The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa
por: Masuku, Sithabiso D., et al.
Publicado: (2023)

Erratum: Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections: Moving towards best practice
por: Peters, Remco P.H., et al.
Publicado: (2022)

Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy
por: Meintjes, Graeme, et al.
Publicado: (2015)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Towards Evidence-Based Implementation of Pharmacogenomics in Southern Africa: Comorbidities and Polypharmacy Profiles across Diseases
por: Soko, Nyarai Desiree, et al.
Publicado: (2023)

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial
por: Waalewijn, Hylke, et al.
Publicado: (2023)

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial
por: Griesel, Rulan, et al.
Publicado: (2021)

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients
por: Swart, Marelize, et al.
Publicado: (2016)

Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa
por: Brennan, Alana T, et al.
Publicado: (2023)

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022)

Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors
por: Pepper, Dominique J, et al.
Publicado: (2010)

Weight gain during the dolutegravir transition in the African Cohort Study
por: Esber, Allahna L., et al.
Publicado: (2022)

Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis
por: Mazanhanga, Marian, et al.
Publicado: (2023)

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
por: Meintjes, Graeme, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lrfjk4h62rkmnu4s3h61shdt7e